Chong Kun Dang Pharmaceutical Corp
KRX:185750
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
86 000
133 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Chong Kun Dang Pharmaceutical Corp
Chong Kun Dang Pharmaceutical Corp
Income from Continuing Operations
Chong Kun Dang Pharmaceutical Corp
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Chong Kun Dang Pharmaceutical Corp
KRX:185750
|
Income from Continuing Operations
₩213.6B
|
CAGR 3-Years
33%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Yuhan Corp
KRX:000100
|
Income from Continuing Operations
₩162.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
30%
|
CAGR 10-Years
5%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Income from Continuing Operations
-₩35.4B
|
CAGR 3-Years
48%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Income from Continuing Operations
₩181.6B
|
CAGR 3-Years
26%
|
CAGR 5-Years
34%
|
CAGR 10-Years
16%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Income from Continuing Operations
₩10.8B
|
CAGR 3-Years
167%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-1%
|
|
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Income from Continuing Operations
₩16.5B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
81%
|
CAGR 10-Years
16%
|
|
Chong Kun Dang Pharmaceutical Corp
Glance View
Chong Kun Dang Pharmaceutical Corp. engages in the manufacture, distribution, research, and development of pharmaceuticals. The company is headquartered in Seoul, Seoul. The company went IPO on 2013-12-06. The firm is mainly involved in the production and sale of prescription drugs such as antidiabetic treatments, cerebrovascular disease treatments, hypertension treatments and hyperlipidemia therapies. In addition, the Company provides over the counter (OTC) drugs including penzal, prefermine and modcol; quasi-drugs including insecticides and hair dyes; and health functional food. The firm sells products in domestic and overseas markets.
See Also
What is Chong Kun Dang Pharmaceutical Corp's Income from Continuing Operations?
Income from Continuing Operations
213.6B
KRW
Based on the financial report for Dec 31, 2023, Chong Kun Dang Pharmaceutical Corp's Income from Continuing Operations amounts to 213.6B KRW.
What is Chong Kun Dang Pharmaceutical Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
39%
Over the last year, the Income from Continuing Operations growth was 167%. The average annual Income from Continuing Operations growth rates for Chong Kun Dang Pharmaceutical Corp have been 33% over the past three years , 39% over the past five years .
You don't have any saved screeners yet
